Fig. 3: ΔgD-2-vaccinated HSV-1-seropositive animals are protected from subsequent HSV-2 skin challenge. | npj Vaccines

Fig. 3: ΔgD-2-vaccinated HSV-1-seropositive animals are protected from subsequent HSV-2 skin challenge.

From: Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity

Fig. 3

Three weeks following boost vaccination, female (closed symbols) and male (open symbols) mice were challenged on the skin with 100 × LD90 (5 × 106 pfu/mouse) of HSV-2 clinical isolate, SD90. a Disease scores (blinded) and b percentage survival following HSV-2 challenge. HSV-1+, ΔgD-2 n = 46; HSV-1+, rgD-2/alum-MPL n = 10; HSV-1+, VD60 n = 23; Naïve, ΔgD-2 n = 20; Naïve, VD60 n = 20 from three independent experiments. Survival was compared by Gehan–Breslow-Wilcoxon test (*p < 0.05, ****p < 0.0001, and ns not significant).

Back to article page